Skip to main content
SpringerLink
Log in

Assays to Measure Suppression of Type I Interferon Responses by Filovirus VP35 Proteins

  • Protocol
  • First Online:
Ebolaviruses

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1628))

  • 1799 Accesses

Abstract

Innate immunity is the first line of defense against virus infections and is marked by production of type I interferons (IFN), a family of cytokines that includes IFN-β and several IFN-αs. For the filoviruses and many other RNA viruses that replicate in the cytoplasm, the RIG-I-like pattern recognition receptors (RLRs) are potential triggers of IFN production. To counteract such innate antiviral responses, many viruses encode proteins that antagonize RLR signaling. Ebola virus (EBOV) and other filoviruses produce VP35 proteins that block IFN induction via RLR signaling. We describe here cell-based reporter gene assays that quantify the IFN-antagonist function of filovirus VP35 proteins by assessing activation of the IFN-β promoter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sanchez A, Wagoner KE, Rollin PE (2007) Sequence-based human leukocyte antigen-B typing of patients infected with Ebola virus in Uganda in 2000: identification of alleles associated with fatal and nonfatal disease outcomes. J Infect Dis 196(Suppl 2):S329–S336. doi:10.1086/520588

    Article  CAS  PubMed  Google Scholar 

  2. Messaoudi I, Amarasinghe GK, Basler CF (2015) Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat Rev Microbiol 13(11):663–676. doi:10.1038/nrmicro3524

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Basler CF, Amarasinghe GK (2009) Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res 29(9):511–520. doi:10.1089/jir.2009.0076

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Cardenas WB, Loo YM, Gale M Jr, Hartman AL, Kimberlin CR, Martinez-Sobrido L, Saphire EO, Basler CF (2006) Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol 80(11):5168–5178. doi:10.1128/JVI.02199-05

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Spiropoulou CF, Ranjan P, Pearce MB, Sealy TK, Albarino CG, Gangappa S, Fujita T, Rollin PE, Nichol ST, Ksiazek TG, Sambhara S (2009) RIG-I activation inhibits ebolavirus replication. Virology 392(1):11–15. doi:10.1016/j.virol.2009.06.032

    Article  CAS  PubMed  Google Scholar 

  6. Hartman AL, Ling L, Nichol ST, Hibberd ML (2008) Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J Virol 82(11):5348–5358. doi:10.1128/JVI.00215-08

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Prins KC, Binning JM, Shabman RS, Leung DW, Amarasinghe GK, Basler CF (2010) Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function. J Virol 84(20):10581–10591. doi:10.1128/JVI.00925-10. JVI.00925-10 [pii]

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Leung DW, Prins KC, Borek DM, Farahbakhsh M, Tufariello JM, Ramanan P, Nix JC, Helgeson LA, Otwinowski Z, Honzatko RB, Basler CF, Amarasinghe GK (2010) Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat Struct Mol Biol 17(2):165–172. doi:10.1038/nsmb.1765

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Luthra P, Ramanan P, Mire CE, Weisend C, Tsuda Y, Yen B, Liu G, Leung DW, Geisbert TW, Ebihara H, Amarasinghe GK, Basler CF (2013) Mutual antagonism between the Ebola virus VP35 protein and the RIG-I activator PACT determines infection outcome. Cell Host Microbe 14(1):74–84. doi:10.1016/j.chom.2013.06.010

    Article  CAS  PubMed  Google Scholar 

  10. Prins KC, Cardenas WB, Basler CF (2009) Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1. J Virol 83(7):3069–3077. doi:10.1128/JVI.01875-08

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Chang TH, Kubota T, Matsuoka M, Jones S, Bradfute SB, Bray M, Ozato K (2009) Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog 5(6):e1000493. doi:10.1371/journal.ppat.1000493

    Article  PubMed  PubMed Central  Google Scholar 

  12. Kubota T, Matsuoka M, Chang TH, Tailor P, Sasaki T, Tashiro M, Kato A, Ozato K (2008) Virus infection triggers SUMOylation of IRF3 and IRF7, leading to the negative regulation of type I interferon gene expression. J Biol Chem 283(37):25660–25670. doi:10.1074/jbc.M804479200

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Greer LF 3rd, Szalay AA (2002) Imaging of light emission from the expression of luciferases in living cells and organisms: a review. Luminescence 17(1):43–74. doi:10.1002/bio.676. [pii]

    Article  CAS  PubMed  Google Scholar 

  14. Kato H, Sato S, Yoneyama M, Yamamoto M, Uematsu S, Matsui K, Tsujimura T, Takeda K, Fujita T, Takeuchi O, Akira S (2005) Cell type-specific involvement of RIG-I in antiviral response. Immunity 23(1):19–28. doi:10.1016/j.immuni.2005.04.010

    Article  CAS  PubMed  Google Scholar 

  15. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e Sousa C, Matsuura Y, Fujita T, Akira S (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441(7089):101–105

    Article  CAS  PubMed  Google Scholar 

  16. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, Fujita T (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5(7):730–737. doi:10.1038/ni1087

    Article  CAS  PubMed  Google Scholar 

  17. Basler CF, Wang X, Muhlberger E, Volchkov V, Paragas J, Klenk HD, Garcia-Sastre A, Palese P (2000) The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc Natl Acad Sci U S A 97(22):12289–12294. doi:10.1073/pnas.220398297

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Baum A, Sachidanandam R, Garcia-Sastre A (2010) Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing. Proc Natl Acad Sci U S A 107(37):16303–16308. doi:10.1073/pnas.1005077107

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Rajsbaum R, Versteeg GA, Schmid S, Maestre AM, Belicha-Villanueva A, Martinez-Romero C, Patel JR, Morrison J, Pisanelli G, Miorin L, Laurent-Rolle M, Moulton HM, Stein DA, Fernandez-Sesma A, tenOever BR, Garcia-Sastre A (2014) Unanchored K48-linked polyubiquitin synthesized by the E3-ubiquitin ligase TRIM6 stimulates the interferon-IKKepsilon kinase-mediated antiviral response. Immunity 40(6):880–895. doi:10.1016/j.immuni.2014.04.018

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Microbial Pathogenesis, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA, USA

    Priya Luthra & Christopher F. Basler

Authors
  1. Priya Luthra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher F. Basler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher F. Basler .

Editor information

Editors and Affiliations

  1. Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany

    Thomas Hoenen

  2. Friedrich-Loeffler-Institut, Greifswald - Insel Riems, Germany

    Allison Groseth

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media LLC

About this protocol

Cite this protocol

Luthra, P., Basler, C.F. (2017). Assays to Measure Suppression of Type I Interferon Responses by Filovirus VP35 Proteins. In: Hoenen, T., Groseth, A. (eds) Ebolaviruses. Methods in Molecular Biology, vol 1628. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7116-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7116-9_10

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-7115-2

  • Online ISBN: 978-1-4939-7116-9

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation